Do analysts recommend SPRO or PYRGF?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spero Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 PyroGenesis Canada 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media prefer SPRO or PYRGF?

In the previous week, Spero Therapeutics had 1 more articles in the media than PyroGenesis Canada. MarketBeat recorded 2 mentions for Spero Therapeutics and 1 mentions for PyroGenesis Canada. Spero Therapeutics' average media sentiment score of 1.42 beat PyroGenesis Canada's score of 0.00 indicating that Spero Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spero Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PyroGenesis Canada 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend TNYA or PYRGF?

Tenaya Therapeutics presently has a consensus price target of $4.00, indicating a potential upside of 461.96%. Given Tenaya Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Tenaya Therapeutics is more favorable than PyroGenesis Canada. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tenaya Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86 PyroGenesis Canada 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts rate ORMP or PYRGF?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 PyroGenesis Canada 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media refer more to ORMP or PYRGF?

In the previous week, Oramed Pharmaceuticals had 5 more articles in the media than PyroGenesis Canada. MarketBeat recorded 6 mentions for Oramed Pharmaceuticals and 1 mentions for PyroGenesis Canada. Oramed Pharmaceuticals' average media sentiment score of 1.18 beat PyroGenesis Canada's score of 0.00 indicating that Oramed Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oramed Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PyroGenesis Canada 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate PYRGF or NGEN?

NervGen Pharma has a consensus price target of $18.00, suggesting a potential upside of 837.50%. Given NervGen Pharma's stronger consensus rating and higher probable upside, analysts plainly believe NervGen Pharma is more favorable than PyroGenesis Canada. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PyroGenesis Canada 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 NervGen Pharma 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 2.80

Which has better earnings and valuation, PYRGF or NGEN?

NervGen Pharma has lower revenue, but higher earnings than PyroGenesis Canada. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PyroGenesis Canada $9.14M 4.28 -$21.12M -$0.04 N/A NervGen Pharma N/A N/A N/A N/A N/A

Is PYRGF or NGEN more profitable?

NervGen Pharma has a net margin of 0.00% compared to PyroGenesis Canada's net margin of -115.14%. Company Net Margins Return on Equity Return on Assets PyroGenesis Canada -115.14% N/A -60.81% NervGen Pharma N/A N/A N/A

Does the media prefer PYRGF or NGEN?

In the previous week, NervGen Pharma had 3 more articles in the media than PyroGenesis Canada. MarketBeat recorded 4 mentions for NervGen Pharma and 1 mentions for PyroGenesis Canada. NervGen Pharma's average media sentiment score of 0.39 beat PyroGenesis Canada's score of 0.00 indicating that NervGen Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PyroGenesis Canada 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NervGen Pharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend PYRGF or OTLK?

Oncobiologics has a consensus price target of $6.50, indicating a potential upside of 432.79%. Given Oncobiologics' stronger consensus rating and higher probable upside, analysts plainly believe Oncobiologics is more favorable than PyroGenesis Canada. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PyroGenesis Canada 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Oncobiologics 1 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is PYRGF or OTLK more profitable?

Oncobiologics has a net margin of 0.00% compared to PyroGenesis Canada's net margin of -115.14%. Company Net Margins Return on Equity Return on Assets PyroGenesis Canada -115.14% N/A -60.81% Oncobiologics N/A N/A -291.28%

Does the media favor PYRGF or OTLK?

In the previous week, Oncobiologics had 11 more articles in the media than PyroGenesis Canada. MarketBeat recorded 12 mentions for Oncobiologics and 1 mentions for PyroGenesis Canada. Oncobiologics' average media sentiment score of 0.90 beat PyroGenesis Canada's score of 0.00 indicating that Oncobiologics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PyroGenesis Canada 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Oncobiologics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

PyroGenesis Canada (PYRGF) Competitors

$0.19 0.00 (0.00%)

As of 06/12/2026 03:55 PM Eastern

Compare

PYRGF vs. SPRO, TNYA, ORMP, NGEN, and OTLK

Should you buy PyroGenesis Canada stock or one of its competitors? MarketBeat compares PyroGenesis Canada with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with PyroGenesis Canada include Spero Therapeutics (SPRO), Tenaya Therapeutics (TNYA), Oramed Pharmaceuticals (ORMP), NervGen Pharma (NGEN), and Oncobiologics (OTLK). These companies are all part of the "pharmaceutical products" industry.

How does PyroGenesis Canada compare to Spero Therapeutics?

Spero Therapeutics (NASDAQ:SPRO) and PyroGenesis Canada (NASDAQ:PYRGF) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, media sentiment, dividends, earnings, valuation and risk.

25.6% of Spero Therapeutics shares are owned by institutional investors. Comparatively, 0.0% of PyroGenesis Canada shares are owned by institutional investors. 2.9% of Spero Therapeutics shares are owned by company insiders. Comparatively, 47.7% of PyroGenesis Canada shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spero Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
PyroGenesis Canada	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Spero Therapeutics has higher revenue and earnings than PyroGenesis Canada. PyroGenesis Canada is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spero Therapeutics	$66.80M	2.47	$8.57M	$0.24	11.88
PyroGenesis Canada	$9.14M	4.28	-$21.12M	-$0.04	N/A

Spero Therapeutics has a net margin of 24.90% compared to PyroGenesis Canada's net margin of -115.14%. Spero Therapeutics' return on equity of 35.58% beat PyroGenesis Canada's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spero Therapeutics	24.90%	35.58%	24.95%
PyroGenesis Canada	-115.14%	N/A	-60.81%

In the previous week, Spero Therapeutics had 1 more articles in the media than PyroGenesis Canada. MarketBeat recorded 2 mentions for Spero Therapeutics and 1 mentions for PyroGenesis Canada. Spero Therapeutics' average media sentiment score of 1.42 beat PyroGenesis Canada's score of 0.00 indicating that Spero Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spero Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PyroGenesis Canada	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Spero Therapeutics has a beta of 1.45, meaning that its stock price is 45% more volatile than the broader market. Comparatively, PyroGenesis Canada has a beta of 0.19, meaning that its stock price is 81% less volatile than the broader market.

Summary

Spero Therapeutics beats PyroGenesis Canada on 12 of the 14 factors compared between the two stocks.

How does PyroGenesis Canada compare to Tenaya Therapeutics?

Tenaya Therapeutics (NASDAQ:TNYA) and PyroGenesis Canada (NASDAQ:PYRGF) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends, media sentiment and valuation.

PyroGenesis Canada has higher revenue and earnings than Tenaya Therapeutics. PyroGenesis Canada is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tenaya Therapeutics	N/A	N/A	-$90.60M	-$0.47	N/A
PyroGenesis Canada	$9.14M	4.28	-$21.12M	-$0.04	N/A

Tenaya Therapeutics has a net margin of 0.00% compared to PyroGenesis Canada's net margin of -115.14%. PyroGenesis Canada's return on equity of 0.00% beat Tenaya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tenaya Therapeutics	N/A	-80.56%	-65.21%
PyroGenesis Canada	-115.14%	N/A	-60.81%

In the previous week, Tenaya Therapeutics and Tenaya Therapeutics both had 1 articles in the media. Tenaya Therapeutics' average media sentiment score of 1.87 beat PyroGenesis Canada's score of 0.00 indicating that Tenaya Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Tenaya Therapeutics	Very Positive
PyroGenesis Canada	Neutral

Tenaya Therapeutics has a beta of 2.82, meaning that its share price is 182% more volatile than the broader market. Comparatively, PyroGenesis Canada has a beta of 0.19, meaning that its share price is 81% less volatile than the broader market.

Tenaya Therapeutics presently has a consensus price target of $4.00, indicating a potential upside of 461.96%. Given Tenaya Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Tenaya Therapeutics is more favorable than PyroGenesis Canada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tenaya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
PyroGenesis Canada	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

90.5% of Tenaya Therapeutics shares are owned by institutional investors. Comparatively, 0.0% of PyroGenesis Canada shares are owned by institutional investors. 2.5% of Tenaya Therapeutics shares are owned by company insiders. Comparatively, 47.7% of PyroGenesis Canada shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Tenaya Therapeutics beats PyroGenesis Canada on 9 of the 15 factors compared between the two stocks.

How does PyroGenesis Canada compare to Oramed Pharmaceuticals?

Oramed Pharmaceuticals (NASDAQ:ORMP) and PyroGenesis Canada (NASDAQ:PYRGF) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk.

In the previous week, Oramed Pharmaceuticals had 5 more articles in the media than PyroGenesis Canada. MarketBeat recorded 6 mentions for Oramed Pharmaceuticals and 1 mentions for PyroGenesis Canada. Oramed Pharmaceuticals' average media sentiment score of 1.18 beat PyroGenesis Canada's score of 0.00 indicating that Oramed Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oramed Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PyroGenesis Canada	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Oramed Pharmaceuticals has a net margin of 0.00% compared to PyroGenesis Canada's net margin of -115.14%. PyroGenesis Canada's return on equity of 0.00% beat Oramed Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oramed Pharmaceuticals	N/A	-5.37%	-4.83%
PyroGenesis Canada	-115.14%	N/A	-60.81%

Oramed Pharmaceuticals has higher earnings, but lower revenue than PyroGenesis Canada. PyroGenesis Canada is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oramed Pharmaceuticals	$2M	79.20	$64.05M	$2.59	1.49
PyroGenesis Canada	$9.14M	4.28	-$21.12M	-$0.04	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oramed Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
PyroGenesis Canada	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Oramed Pharmaceuticals has a beta of 1.26, indicating that its share price is 26% more volatile than the broader market. Comparatively, PyroGenesis Canada has a beta of 0.19, indicating that its share price is 81% less volatile than the broader market.

12.7% of Oramed Pharmaceuticals shares are held by institutional investors. Comparatively, 0.0% of PyroGenesis Canada shares are held by institutional investors. 17.8% of Oramed Pharmaceuticals shares are held by company insiders. Comparatively, 47.7% of PyroGenesis Canada shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Oramed Pharmaceuticals beats PyroGenesis Canada on 11 of the 14 factors compared between the two stocks.

How does PyroGenesis Canada compare to NervGen Pharma?

PyroGenesis Canada (NASDAQ:PYRGF) and NervGen Pharma (NASDAQ:NGEN) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, dividends, earnings, profitability and institutional ownership.

NervGen Pharma has lower revenue, but higher earnings than PyroGenesis Canada.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PyroGenesis Canada	$9.14M	4.28	-$21.12M	-$0.04	N/A
NervGen Pharma	N/A	N/A	N/A	N/A	N/A

0.0% of PyroGenesis Canada shares are held by institutional investors. 47.7% of PyroGenesis Canada shares are held by insiders. Comparatively, 5.8% of NervGen Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

NervGen Pharma has a consensus price target of $18.00, suggesting a potential upside of 837.50%. Given NervGen Pharma's stronger consensus rating and higher probable upside, analysts plainly believe NervGen Pharma is more favorable than PyroGenesis Canada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PyroGenesis Canada	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
NervGen Pharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.80

In the previous week, NervGen Pharma had 3 more articles in the media than PyroGenesis Canada. MarketBeat recorded 4 mentions for NervGen Pharma and 1 mentions for PyroGenesis Canada. NervGen Pharma's average media sentiment score of 0.39 beat PyroGenesis Canada's score of 0.00 indicating that NervGen Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PyroGenesis Canada	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NervGen Pharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

NervGen Pharma has a net margin of 0.00% compared to PyroGenesis Canada's net margin of -115.14%.

Company	Net Margins	Return on Equity	Return on Assets
PyroGenesis Canada	-115.14%	N/A	-60.81%
NervGen Pharma	N/A	N/A	N/A

Summary

NervGen Pharma beats PyroGenesis Canada on 8 of the 11 factors compared between the two stocks.

How does PyroGenesis Canada compare to Oncobiologics?

PyroGenesis Canada (NASDAQ:PYRGF) and Oncobiologics (NASDAQ:OTLK) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, institutional ownership, media sentiment, profitability and earnings.

PyroGenesis Canada has a beta of 0.19, suggesting that its share price is 81% less volatile than the broader market. Comparatively, Oncobiologics has a beta of 0.94, suggesting that its share price is 6% less volatile than the broader market.

PyroGenesis Canada has higher revenue and earnings than Oncobiologics. PyroGenesis Canada is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PyroGenesis Canada	$9.14M	4.28	-$21.12M	-$0.04	N/A
Oncobiologics	$1.35M	126.56	-$62.42M	-$1.17	N/A

Oncobiologics has a net margin of 0.00% compared to PyroGenesis Canada's net margin of -115.14%.

Company	Net Margins	Return on Equity	Return on Assets
PyroGenesis Canada	-115.14%	N/A	-60.81%
Oncobiologics	N/A	N/A	-291.28%

0.0% of PyroGenesis Canada shares are held by institutional investors. Comparatively, 11.2% of Oncobiologics shares are held by institutional investors. 47.7% of PyroGenesis Canada shares are held by insiders. Comparatively, 1.8% of Oncobiologics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Oncobiologics has a consensus price target of $6.50, indicating a potential upside of 432.79%. Given Oncobiologics' stronger consensus rating and higher probable upside, analysts plainly believe Oncobiologics is more favorable than PyroGenesis Canada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PyroGenesis Canada	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Oncobiologics	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Oncobiologics had 11 more articles in the media than PyroGenesis Canada. MarketBeat recorded 12 mentions for Oncobiologics and 1 mentions for PyroGenesis Canada. Oncobiologics' average media sentiment score of 0.90 beat PyroGenesis Canada's score of 0.00 indicating that Oncobiologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PyroGenesis Canada	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oncobiologics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Oncobiologics beats PyroGenesis Canada on 10 of the 15 factors compared between the two stocks.

Get PyroGenesis Canada News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PYRGF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PYRGF vs. The Competition

Export

Metric	PyroGenesis Canada	Pharmaceutical Industry	Industrials Sector	NASDAQ Exchange
Market Cap	$39.14M	$979.54M	$9.43B	$12.05B
Dividend Yield	N/A	4.84%	3.55%	5.66%
P/E Ratio	-3.15	1.45	25.55	24.42
Price / Sales	4.28	120.49	5,068.43	111.24
Price / Cash	N/A	20.06	27.58	37.92
Price / Book	-18.90	7.85	4.73	6.82
Net Income	-$21.12M	-$4.88M	$793.52M	$337.56M
7 Day Performance	7.63%	0.64%	4.68%	1.17%
1 Month Performance	-38.32%	-0.16%	5.16%	3.16%
1 Year Performance	-45.12%	47.51%	30.25%	30.58%

PyroGenesis Canada Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PYRGF PyroGenesis Canada	N/A	$0.19 flat	N/A	-45.1%	$39.14M	$9.14M	N/A	90	Gap Down
SPRO Spero Therapeutics	1.646 of 5 stars	$2.85 +5.6%	N/A	+0.7%	$156.33M	$66.80M	11.88	150	Positive News
TNYA Tenaya Therapeutics	2.5488 of 5 stars	$0.71 -1.1%	$4.00 +462.0%	+20.3%	$156.20M	N/A	N/A	110	Positive News
ORMP Oramed Pharmaceuticals	2.2922 of 5 stars	$3.87 +1.8%	N/A	+81.7%	$155.52M	$2M	1.49	10	Positive News
NGEN NervGen Pharma	4.3064 of 5 stars	$1.92 +1.6%	$18.00 +837.5%	N/A	$154.81M	N/A	N/A	N/A	Short Interest Increase

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PYRGF) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PyroGenesis Canada (PYRGF) Competitors

PYRGF vs. SPRO, TNYA, ORMP, NGEN, and OTLK

How does PyroGenesis Canada compare to Spero Therapeutics?

Summary

How does PyroGenesis Canada compare to Tenaya Therapeutics?

Summary

How does PyroGenesis Canada compare to Oramed Pharmaceuticals?

Summary

How does PyroGenesis Canada compare to NervGen Pharma?

Summary

How does PyroGenesis Canada compare to Oncobiologics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PYRGF vs. The Competition

PyroGenesis Canada Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PyroGenesis Canada (PYRGF) Competitors

PYRGF vs. SPRO, TNYA, ORMP, NGEN, and OTLK

How does PyroGenesis Canada compare to Spero Therapeutics?

Do insiders and institutionals believe in SPRO or PYRGF?

Do analysts recommend SPRO or PYRGF?

Which has higher valuation and earnings, SPRO or PYRGF?

Is SPRO or PYRGF more profitable?

Does the media prefer SPRO or PYRGF?

Which has more risk & volatility, SPRO or PYRGF?

Summary

How does PyroGenesis Canada compare to Tenaya Therapeutics?

Which has stronger valuation and earnings, TNYA or PYRGF?

Is TNYA or PYRGF more profitable?

Does the media refer more to TNYA or PYRGF?

Which has more volatility & risk, TNYA or PYRGF?

Do analysts recommend TNYA or PYRGF?

Do insiders and institutionals have more ownership in TNYA or PYRGF?

Summary

How does PyroGenesis Canada compare to Oramed Pharmaceuticals?

Does the media refer more to ORMP or PYRGF?

Is ORMP or PYRGF more profitable?

Which has better valuation and earnings, ORMP or PYRGF?

Do analysts rate ORMP or PYRGF?

Which has more risk and volatility, ORMP or PYRGF?

Do institutionals and insiders have more ownership in ORMP or PYRGF?

Summary

How does PyroGenesis Canada compare to NervGen Pharma?

Which has better earnings and valuation, PYRGF or NGEN?

Do insiders & institutionals have more ownership in PYRGF or NGEN?

Do analysts rate PYRGF or NGEN?

Does the media prefer PYRGF or NGEN?

Is PYRGF or NGEN more profitable?

Summary

How does PyroGenesis Canada compare to Oncobiologics?

Which has more risk & volatility, PYRGF or OTLK?

Which has higher valuation & earnings, PYRGF or OTLK?

Is PYRGF or OTLK more profitable?

Do institutionals and insiders hold more shares of PYRGF or OTLK?

Do analysts recommend PYRGF or OTLK?

Does the media favor PYRGF or OTLK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PYRGF vs. The Competition

PyroGenesis Canada Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools